Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 20/20 | 0.59 |
| ▸ | HTR3A | P46098 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL240262 | 1.00 | HRH3 (0.59) | HRH3HTR3AKCNH2 | |
| SCHEMBL251362 | 0.86 | HRH3 (0.66) | HRH3HTR3AKCNH2 | |
| SCHEMBL251361 | 0.86 | HRH3 (0.66) | HRH3HTR3AKCNH2 | |
| SCHEMBL239509 | 0.81 | HRH3 (0.68) | HRH3HTR3AKCNH2 | |
| SCHEMBL239508 | 0.81 | HRH3 (0.68) | HRH3HTR3AKCNH2 | |
| SCHEMBL239641 | 0.80 | HRH3 (0.61) | HRH3HTR3AKCNH2 | |
| SCHEMBL239642 | 0.80 | HRH3 (0.61) | HRH3HTR3AKCNH2 | |
| SCHEMBL240249 | 0.80 | HRH3 (0.67) | HRH3HTR3AKCNH2 | |
| SCHEMBL240250 | 0.80 | HRH3 (0.67) | HRH3HTR3AKCNH2 | |
| SCHEMBL1373701 | 0.74 | HRH3 (1.00) | HRH3HTR3AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912183-B2 | Substituted pyridazine derivatives | CEPHALON, INC. (US) | 2014-12-16 | — | — | US | claimed |
| EP-2252593-B1 | SUBSTITUTED PYRIDAZINE DERIVATIVES WHICH HAVE HISTAMINE H3 ANTAGONIST ACTIVITY | CEPHALON INC (US) | 2014-04-23 | — | — | EP | claimed |
| US-20120004231-A1 | Substituted Pyridazine Derivatives | CEPHALON, INC. (US) | 2012-01-05 | — | — | US | claimed |
| US-8076331-B2 | Substituted pyridazine derivatives | CEPHALON, INC. (US) | 2011-12-13 | — | — | US | claimed |
| US-20100311752-A1 | Substituted pyridazine derivatives | CEPHALON, INC. (US) | 2010-12-09 | — | — | US | claimed |
| EP-2252593-A1 | SUBSTITUTED PYRIDAZINE DERIVATIVES WHICH HAVE HISTAMINE H3 ANTAGONIST ACTIVITY | Cephalon, Inc. (US) | 2010-11-24 | — | — | EP | claimed |
| WO-2009097306-A1 | SUBSTITUTED PYRIDAZINE DERIVATIVES WHICH HAVE HISTAMINE H3 ANTAGONIST ACTIVITY | CEPHALON, INC. (US) | 2009-08-06 | — | — | WO | claimed |
| US-8912183-B2 | Substituted pyridazine derivatives | CEPHALON, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-8912183-B2 | Substituted pyridazine derivatives | CEPHALON, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-8912183-B2 | Substituted pyridazine derivatives | CEPHALON, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| EP-2752406-A1 | Substituted pyridazine derivatives which have histamine H3 antagonist activity | CEPHALON, INC. (US) | 2014-07-09 | — | — | EP | disclosed |
| EP-2252593-B1 | SUBSTITUTED PYRIDAZINE DERIVATIVES WHICH HAVE HISTAMINE H3 ANTAGONIST ACTIVITY | CEPHALON INC (US) | 2014-04-23 | — | — | EP | disclosed |
| EP-2252593-B1 | SUBSTITUTED PYRIDAZINE DERIVATIVES WHICH HAVE HISTAMINE H3 ANTAGONIST ACTIVITY | CEPHALON INC (US) | 2014-04-23 | — | — | EP | disclosed |
| US-8076331-B2 | Substituted pyridazine derivatives | CEPHALON, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-20100311752-A1 | Substituted pyridazine derivatives | CEPHALON, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100311752-A1 | Substituted pyridazine derivatives | CEPHALON, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100311752-A1 | Substituted pyridazine derivatives | CEPHALON, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| EP-2252593-A1 | SUBSTITUTED PYRIDAZINE DERIVATIVES WHICH HAVE HISTAMINE H3 ANTAGONIST ACTIVITY | Cephalon, Inc. (US) | 2010-11-24 | — | — | EP | disclosed |
| WO-2009097306-A1 | SUBSTITUTED PYRIDAZINE DERIVATIVES WHICH HAVE HISTAMINE H3 ANTAGONIST ACTIVITY | CEPHALON, INC. (US) | 2009-08-06 | — | — | WO | disclosed |
| WO-2009097306-A1 | SUBSTITUTED PYRIDAZINE DERIVATIVES WHICH HAVE HISTAMINE H3 ANTAGONIST ACTIVITY | CEPHALON, INC. (US) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004231-A1 | Substituted Pyridazine Derivatives | HRH3, HRH4, HRH2 | HRH3 1/4885HTR3A 26/4885KCNH2 390/4885 |
| US-20100311752-A1 | Substituted pyridazine derivatives | HRH3, HRH4, HRH2 | HRH3 1/4885HTR3A 26/4885KCNH2 390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.